EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

The Australian company, which manufactures its footwear in Australia and just celebrated its 50th anniversary, owns the “UGG ...

Deckers Outdoor Corp., a U.S. footwear designer and distributor, has waged a protracted legal battle against companies around ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Teva Pharma Industries Ltd ADR (NYSE ... and 15% YoY in international markets. Global sales of its brand drugs were robust. AUSTEDO exceeded $1.6 billion in revenues, surpassing the company ...

It would be unique to have a site ready to go and not rely on a green-build. The difference between a panel assembler and a cell manufacturer is apparent at once. Solar panel manufacturers are ...

Deckers Outdoor (DECK – Research Report), the Consumer Cyclical sector company, was revisited by a Wall Street analyst today. Analyst Tom Nikic ...